Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Over 200 passionate programmers participated in The Bucharest Hackathon 2024, and the total prizes exceeded 50,000 dollars

STORM Partners

https://we.tl/t-lk7ZTXr33k Bucharest, 25th of April 2024: On April 14th, the Odeon Theater hosted the second edition of The Bucharest Hackathon, the first hackathon in Romania dedicated to enthusiasts of new technologies. The competition brought together over 200 amateur and senior programmers, both Romanian and foreign, who came from Bucharest as well as from other cities in the country, such as Cluj, Brasov, or Craiova. For 24 hours, they coded and competed in developing software projects that tested the limits of modern technologies. The top three teams won the grand prize of a total value of $30,000, but 25 teams were also selected to receive special prizes from the partners. For the final competition, 35 teams were selected. “ The Bucharest Hackathon is attracting more and more participants. I was impressed by the level of competence of the teams and projects and their achievements in only 24 hours. The jury members, most of whom have international experience, appreciated the location and organization, stating that they felt like they were at a hackathon in Silicon Valley. Genezio was chosen by more than half of the teams to implement their solution. ” Andrei Pitis, CEO & Co-founder of Genezio. “ From the moment we saw the first registrations for the event, we realized that we were going to have a completely different edition: an iconic location, much bolder ideas, much more creative solutions, but also a considerable effort - and so it was. The Bucharest Hackathon was truly an emotional roller-coaster: from the trust in the colleagues on our team to the transformation of an idea into a product, and to the decisive moment when you find out if you are among the winners,” said Flavian Manea, CEO and co-founder of Bware Labs. “At MultiversX, we are proud to support innovation and entrepreneurship in our tech community. The partnership with The Bucharest Hackathon underlines our commitment to the future of technology and innovation in Romania. We are excited to see such creative ideas turned into reality and provide the necessary support for these projects to become successful startups”, Daniel Serb, VP of Business Development of MultiversX. Each of the three winning teams received prizes worth over $10,000, as well as Amazon vouchers worth $15,000, while the teams that won special prizes from the partners received $20,000 in vouchers on the Blast platform, developed by Bware Labs, $10,000 in Genezio vouchers, two startup support prizes from MultiversX, a special prize from Google: Google Nest Hub (2nd Gen) smart speakers, an innovation prize from PiSquared worth $2,500 in vouchers and $2,000 in consulting vouchers from Astrarizon. Fork_Exec, Salty, and Awesome Hackers are this year's winning teams at The Bucharest Hackathon This year’s grand prize of $5,000 was won by the Fork_Exec team, made up of Dejanu Alexandru, Opri Cezar, and Dumitru Iulia. Fork_Exec developed a software solution based on speech recognition and artificial intelligence technologies that allows programmers to automate parts of coding based on voice commands. Second place, worth $3,000, went to the Salty team, composed of Kerimberdi Agayev Kaibov Merdan and Cihan Ilhan. They proposed an application for high school students to receive guidance on complex math problems. The application takes the user’s handwriting and, combining OpenAI and AWS Cloud technologies provides the answer to the problem almost instantly. The third prize, of $2,000, was won by the programmers from the Awesome Hackers team, namely Puiu Răzvan, Ene Cosmina, and Manea Lucas. Awesome Hackers created a neural data collection platform designed to help improve cognitive function and focus. In addition, two of the participating teams will receive support from MultiversX so that their ideas can reach the startup stage (Awesome Hackers and Mental Regression). Among the special prize winners is also the Wildcard team, who received a Nest Hub 2nd Generation from Google. The jury was made up of tech experts, IT entrepreneurs, and top executives from the companies: Genezio, Bware Labs, MultiversX, Google, Stripe, PiSquared, XOXNO, and Amazon Web Services. For this edition, the main partners Genezio and Bware Labs, the co-founding companies of The Bucharest Hackathon project, were joined by the Romanian blockchain company MultiversX. Among the partners of the second edition of The Bucharest Hackathon are the companies Stripe, PiSquared, XOXNO, Google, Amazon Web Services, Astrarizon, and xExchange. The event was sponsored by Orange Romania, AQUA Carpatica, Blue Romania, Domeniile Averești, Komoder Romania, Nespresso Professional, and Good Routine by SECOM, with media and communication partners Republica, Innovation Labs, ETH Bucharest, Caracteristic PR, KCD Romania, and the Student League Electronics. About The Bucharest Hackathon The Bucharest Hackathon is a 24-hour competition dedicated to programmers and enthusiasts of modern technologies, such as AI, Dev Tools, blockchain, and others. Although initially dedicated to those in Bucharest, the event welcomed programmers from other cities or countries in both editions. The event was founded by Bware Labs and Genezio in 2023 to provide enthusiasts of modern technologies with the space, resources, and challenges they need to develop themselves and test both their limits and those of new technologies. About MultiversX MultiversX is a highly scalable, secure, and decentralized blockchain network built from first principles, to solve the two fundamental problems critical for widespread, global adoption: a transition from dialup to broadband, and a significant UX paradigm shift. Media Contact: Dan Voicu, Head of Communications dan.voicu@multiversx.com Distributed by STORM Partners. Contact Adrian Bono for interviews and quotes - adrian.bono@storm.partners or telegram @STORMPartners Contact Details MultiversX Dan Voicu, Head of Communications dan.voicu@multiversx.com Company Website https://multiversx.com/

April 25, 2024 11:07 AM Eastern Daylight Time

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health

Petros Pharmaceuticals Inc

Petros Pharmaceuticals CEO Fady Boctor joined Steve Darling from Proactive to share exciting developments with Proactive, highlighting a new collaboration with Lemonaid Health, a prominent telemedicine provider and subsidiary of 23andMe. Through this collaboration, Lemonaid Health's telehealth platform will offer prescription STENDRA® (avanafil) in all strengths, expanding distribution and enhancing access for patients. Lemonaid Health's extensive reach, having treated over 200,000 patients with erectile dysfunction (ED) to date, positions Petros to serve a broader patient base across the United States effectively. In addition to the collaboration with Lemonaid Health, Boctor discussed the positive results of an initial cohort in Petros' self-selection study. This study compares the use of a Drug Facts Label (DFL) alone to a combination of DFL with a web app. The preliminary results suggest that while the DFL-alone approach may be insufficient for self-selection, the combination with the proposed technology significantly improves outcomes. This study serves as a precursor to Petros' pivotal Phase 2 study, initiated earlier this month, which aims to provide compelling evidence to the FDA. The pivotal study is designed to demonstrate that users can determine the appropriateness of STENDRA® (avanafil) without the need for a physician and prescription. These developments underscore Petros Pharmaceuticals' commitment to leveraging innovative solutions to improve patient access to essential medications and streamline healthcare delivery processes. Contact Details Proactive North America Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

April 25, 2024 10:20 AM Eastern Daylight Time

Video

Hoag Health System Selects PathAI and the AISight Image Management System to Support the Transition To Digital and AI-enabled Pathology

PathAI

PathAI, a leading precision pathology company, today announced that Hoag Health System, the leading health system in the southern California region, will adopt the AISight Image Management System (IMS) as their primary platform, powering their transition to digital pathology. The transition from analog, glass-slide-based pathology to digital pathology continues to accelerate across anatomic pathology, globally. This transition is in part driven by the availability of AI pathology tools that harness machine learning (ML) algorithms to augment and assist the pathologist interpretation. “The transition to digital pathology will unlock dramatic improvements in how care is provided to Hoag’s patients. By utilizing the most advanced image management system on the market with embedded algorithms, we expect to be able to deliver faster turnaround times to our physicians, more accurate and reproducible pathologist assessments, and expand our understanding of how biomarkers can drive optimal care decisions,” said Dr. Michael Brant-Zawadzki, MD, FACR, Hoag Vice President, Research Administration, CATALiST and Addiction. AISight 1 is a cloud-native intelligent enterprise workflow solution that is used by the world's leading laboratories and research centers to power their digital pathology workflows and AI applications. It serves as a central hub for case management, image management, and best-in-class artificial intelligence tools from PathAI and third-party partners, to enable a broad spectrum of histopathology use cases. “Together with our partners, we will continue to pursue our vision to improve patient outcomes with AI-powered technology,” said Eric Walk, MD, FCAP, Chief Medical Officer, PathAI. “We are excited to partner with forward-thinking industry leaders like Hoag who embrace the science of what machine learning algorithms can offer healthcare professionals and how those learnings can augment and empower the important work of pathologists.” According to Dr. John Cupp, MD, Director of Digital Pathology, Hoag Health System and PathAI Advisor, “Hoag is particularly excited to utilize PathAI’s ArtifactDetect algorithm that can improve pathology review, specifically to address pre-analytical factors that typically would delay pathologist review, as well as applying PathAI’s quantitative IHC scoring algorithms to support complex interpretation in PDL1 and HER2.” Importantly, PathAI will collaborate with Hoag and their laboratory information system (LIS) provider to build a bi-directional integration between AISight and their Epic Beaker LIS instance to ensure a fully integrated pathologist experience. “Computational pathology promises to unlock great potential for predictive biomarkers for patients with cancer,” said Dr. David R. Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute. “This is an exciting next step in Hoag’s digital transformation as we continue to look ahead towards healthcare innovations that offer continual advancements in patient care, treatment efficacy, and overall public health outcomes.” 1 AISight is For Research Use Only. Not for use in diagnostic procedures. About Hoag Hoag is a nonprofit, regional health care delivery system in Orange County, California. Delivering world-class, comprehensive, personalized care, Hoag consists of 1,800 top physicians, 16 urgent care facilities, 11 health & wellness centers, and two award-winning hospitals. Hoag offers a comprehensive blend of health care services that includes seven institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, spine, women’s health, and orthopedics through Hoag’s affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and four ambulatory surgical centers. Hoag is the highest ranked hospital in Orange County by U.S. News & World Report and the only OC hospital ranked in the Top 10 in California, as well as a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). For more information, visit hoag.org. About PathAI PathAI is the leading precision pathology company providing software and AI-enabled solutions to all pathologist stakeholders including laboratories, research institutions, and the biopharma industry. Developed with the input of hundreds of pathologists, PathAI’s digital pathology Image Management System, AISight, is the solution of choice for laboratories transitioning to digital workflows. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

April 25, 2024 10:00 AM Eastern Daylight Time

ECLYPSES USHERS IN NEW ERA OF CYBERSECURITY ASSURANCE WITH FIPS 140-3 VALIDATION OF ITS CRYPTOGRAPHIC LIBRARY

Eclypses Inc.

Eclypses, a leader in end-point data protection, today announced that it has successfully secured the Federal Information Processing Standard 140-3 (FIPS 140-3) validation. The Eclypses Cryptographic Library (ECL), which acts as a key component inside its Secure MTE Technology, successfully passed a series of tests conducted by an independent NIST-accredited laboratory. Eclypses is committed to providing its global customers with the most stringently reviewed technology to ensure their users’ data is protected. Secure MTE technology protects data at the application level, and provides endpoint verification, adhering to zero trust principles. "Customers operating in a world of exponential and ever-changing cyber threats need to have trust that their enterprise and customer data is protected,” said David Gomes, chief executive officer, Eclypses. “Attaining FIPS 140-3 certification acknowledges Eclypses' relentless pursuit of excellence in data security. This certification validates our commitment to robust security protocols and paves the way for enhanced trust and reliability for our customers and partners." About FIPS 140-3 Seen as the gold standard in data security, FIPS 140-3 validation proves that Eclypses’ Cryptographic Library effectively and consistently helps the Secure MTE Technology safeguard user data, ensuring that bad actors cannot access valuable information at any point during the data transmission process. FIPS 140-3 is a U.S. government computer security standard used to approve cryptographic modules and covers a wide range of potential applications. With this validation from a National Institute of Standards and Technology (NIST) approved testing laboratory, Eclypses Cryptographic Library (ECL) is now validated. ECL houses all cryptographic algorithms used by Eclypses’ patented Secure MTE technology. Secure MTE provides true end-to-end payload protection through every aspect of a network, regardless of the configuration, and ensures that in the event of a breach, attackers cannot use the data to cause harm. This technology is an added layer of security at a low latency, complementing existing cyber security protocols with real-time speeds. FIPS 140-3 validation gives Eclypses clients confidence that its technology is built upon the highest levels of trust and reliability. “This validation signals a company has completed a strict review process and received validation from one of the most highly regarded security standards bodies in the world,” said Jefferson Dance, chief innovation officer, Eclypses. “With the FIPS 140-3 validation, Eclypses can continue to deliver data security for its finance, healthcare, retail, and critical infrastructure clients.” In order to achieve FIPS 140-3 validation, cryptographic modules are subject to testing by NVLAP-accredited Cryptographic and Security Testing laboratories. The validation for Eclypses was performed by Penumbra Security, Inc. About Eclypses Eclypses sets the new standard for protecting the world’s most sensitive enterprise and customer data. Secure MTE® Technology delivers a transformative cyber security solution by replacing actual data with instantly obsolete, meaningless random streams of values. Even as threat vectors increase and network breaches proliferate, sensitive data is protected for its intended recipients and use. Eclypses was named Best Cybersecurity Solution in the FTF News Technology Innovations Awards in 2022 and 2023. For more information, please visit www.eclypses.com. Contact Details Racepoint Global Anna Halstead +1 617-624-3212 eclypses@racepointglobal.com

April 25, 2024 09:03 AM Eastern Daylight Time

MariMed closes acquisition of a dispensary in Illinois marking the company’s 5th in that state

MariMed Inc

MariMed CEO Jon Levine joined Steve Darling from Proactive to to share the Company’s significant developments, including its recent of Allgreens Dispensary, LLC, which closed on April 9, 2024. The acquisition enabled the Company to operate its 5th Thrive-branded dispensary in Illinois. It followed the recent opening of the Company’s processing facility in Mt. Vernon, Illinois, which enabled the Company to distribute its portfolio of top-selling brands throughout the high-growth state. Illinois surpassed $1.6 billion in adult-use cannabis sales last year, and MariMed looks to continue expanding there as current regulations in Illinois permit operators to own up to 10 dispensaries. In addition to its expansion efforts in Illinois, MariMed has acquired the assets of Our Community Wellness & Compassionate Care Center in Prince George's County, Maryland. This acquisition marks MariMed's second adult-use Thrive Wellness dispensary in Maryland, complementing its existing location in Annapolis. The Company is vertically integrated in Maryland, with a cultivation and processing facility in Hagerstown that distributes MariMed products state-wide. As a company dedicated to developing and distributing great brands and delivering an exceptional customer experience at its retail stores, these recent acquisitions underscore MariMed's commitment to strategic expansion and enhancing its footprint in key cannabis markets. Contact Details Proactive North America Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

April 24, 2024 02:01 PM Eastern Daylight Time

Video

Nevis Brands announces major shots are now for sale in dozens if dispensaries in Missouri

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to announce the successful completion of the initial production run of Major shots in Missouri through its licensee, Stash House Distro. This milestone marks the expansion of Nevis Brands' product offerings into the Missouri market, with three flavors of its 2-ounce Major shots—Fruit Punch, Blackberry Lemonade, and Blueberry—now available for sale. Nevis Brands has previously introduced these products in Washington and Ohio, achieving successful distribution. The Major shots are infused with 100mg of THC and leverage a proprietary formula of flavor and emulsion technology, enabling rapid onset effects in under 20 minutes with minimal cannabis taste. The products are now accessible to consumers in numerous dispensaries across Missouri, further solidifying Nevis Brands' presence in the cannabis beverage market. Additionally, Kueber shared news regarding the restructuring of the company's Promissory Note due to SoRSE Technology Corp., which was initially part of Nevis Brands' purchase of the SoRSE Technology business units "THC Essentials," including the Major brand. Under the revised terms of the agreement, Nevis Brands will pay USD $100,000 by April 30th, 2024, and proceed with periodic payments to retire the note principal by December 31, 2024. This strategic move reflects Nevis Brands' commitment to managing its financial obligations while continuing to expand its product portfolio and market presence. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 24, 2024 01:57 PM Eastern Daylight Time

Video

Creo Medical says NHS case study reveals significant efficiencies from Speedboat technology

Creo Medical Group PLC

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford discusses an NHS case study that showcases the efficacy of Creo's Speedboat technology. In an interview with Proactive's Stephen Gunnion, Gulliford discussed the case study, which was conducted by the NHS Supply Chain responsible for the procurement of devices and consumables worth approximately £4 billion. This study, which analysed 130 cases, demonstrated significant cost savings and clinical outcomes, with almost £700,000 saved and reductions in hospital stay times for patients, which potentially impacts surgical and endoscopy waiting lists significantly. Gulliford also outlined future plans involving routine guidance by NICE and ongoing partnerships with the NHS Supply Chain to further implement and leverage the technology across UK trusts. He emphasized the dual benefits of clinical excellence and cost savings. Additional updates from Gulliford included progress in other areas of the company, like advancements with robotics and polymeric technology, and significant regulatory developments. Overall, these initiatives are part of Creo’s strategy to expand its product range and increase utilisation of its technology not just in the UK but globally, he added. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 24, 2024 10:56 AM Eastern Daylight Time

Video

ANGLE partners with AstraZeneca in groundbreaking oncology contract

ANGLE PLC

ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with news the company has entered a significant contract with AstraZeneca, marking its second major collaboration with a large pharmaceutical company. Newland, expressed enthusiasm about this development, noting the contract's potential to expand ANGLE's services in oncology trials. The initial phase of the contract is valued at £150,000, but it holds substantial potential due to the possibility of implementing a new assay in numerous cancer trials involving AstraZeneca. The scope of the collaboration includes the development of assays for examining proteins on cancer cells across multiple trials, with potential earnings of £2,000 per time point in over 460 trials. The contract also enables ANGLE to further validate and possibly expand its FDA approvals, positioning it uniquely as a provider of comprehensive diagnostic solutions internationally. Looking ahead, the successful execution of the contract could lead to extensive financial gains for ANGLE PLC, ranging into the tens or even hundreds of millions of pounds, particularly as AstraZeneca's trials progress and its drugs approach commercial launch. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 24, 2024 10:52 AM Eastern Daylight Time

Video

Shareholder to Return to Berkshire Hathaway Annual Meeting One Year After Arrest in Omaha

NLPC

As the annual meeting for Berkshire Hathaway Inc. on May 4 in Omaha approaches, National Legal and Policy Center Chairman Peter Flaherty plans a return to the same stage where last year, while presenting NLPC’s shareholder proposal, Warren Buffett cut off his speech and Flaherty was arrested. Trumped-up charges against Flaherty were later dropped. NLPC has another proposal on Berkshire’s 2024 proxy statement and Flaherty is scheduled to speak on the measure for his allotted five minutes. The nonprofit corporate watchdog released a short video that briefly recounts last year’s incident and points out Mr. Buffett’s contradictory positions on how he manages shareholder meetings. The video may be found on NLPC’s website: https://nlpc.org/corporate-integrity-project/video-nlpc-returns-to-berkshire-hathaway-annual-meeting-one-year-after-chairmans-arrest/ The video highlights a past statement Mr. Buffett made to CNBC. Responding to an interviewer’s question about Berkshire allowing investors who attend the popular annual meeting to ask any question they want, Mr. Buffett responded, “We’ve got a partnership feeling toward the people who have given us their money, and we don’t screen ‘em, and they can ask whatever’s on their mind.” However, last year Mr. Buffett made an exception to that principle when Peter Flaherty – during his official remarks presenting NLPC’s shareholder proposal, which was on the meeting agenda – brought up Mr. Buffett’s relationship with billionaire Bill Gates, their shared philanthropic efforts, and Mr. Gates’s troubling relationship with deceased pedophile Jeffrey Epstein. At that point, Flaherty’s microphone was silenced, and security and Omaha law enforcement forcibly walked him out of the arena and to a local police precinct, where he was arrested, booked, fingerprinted and held for about three hours. As NLPC argued last year in a report to the Securities and Exchange Commission, Berkshire’s identity is inextricably linked with Mr. Buffett’s. As such, his philanthropic activities and personal associations are fair targets for criticism, unlike those of nearly any other corporate Chairman/CEO. NLPC also filed a complaint with the SEC late last year over Berkshire’s inappropriate treatment of Flaherty at the meeting. “Warren Buffett boasts that shareholders can ask questions on any topic they desire, but I guess that doesn’t include questions about Bill Gates or Jeffrey Epstein,” Flaherty said. This year’s shareholder proposal addresses concerns about Berkshire’s risk vulnerabilities over the amount its sales and supply chain depend on China. Subsidiaries such as Duracell and Fruit of the Loom, and significant investments such as Apple and Coca-Cola, substantially depend on access to the communist nation. NLPC also filed a proxy memo with the SEC in support of this year’s proposal. The video released by NLPC concludes by wondering if Mr. Buffett will keep his word, and let all Berkshire investors say “whatever is on their mind.” For more information or to schedule an interview with Paul Chesser, contact Dan Rene at 202-329-8357 or drene@nlpc.org. Please visit http://www.nlpc.org. Founded in 1991, the National Legal and Policy Center promotes ethics in public life through research, investigation, education and legal action. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

April 24, 2024 09:00 AM Eastern Daylight Time

1 2 3 4 5 ... 272